The fight against cancer seems to be a never-ending battle. This deadly disease has been around for quite some time, and it has taken the lives of many. This is where cancer research comes into the picture, and Seattle Genetics is one of the leaders in the field today. Seattle Genetics is a Seattle-based biotech company that specializes in antibody-based therapies. These therapies are some of the most efficient cancer fighting medications on the market. They simply outperform their predecessors of the past by leaps and bounds. ADCETRIS is the flagship drug here, and it is now being used in over 65 countries worldwide.
Thanks to the brilliant business negotiations of Dr. Clay Siegall, this medication has been entered into multiple strategic licenses with GlaxoSmithKline, Pfizer and Genentech. As of today, ADCETRIS has brought in over $350 million in revenue for the company. Siegall, whom is the CEO, president and founder of Seattle Genetics, has taken this biotech giant straight to the top. He has a long history of working in this business, and he’s one of the most accomplished in cancer research. The guy has a Ph.D in Genetics from George Washington University, and he has a B.S. in Zoology from the University of Maryland. Siegall’s goal is to save lives and that’s just what he is doing. His passion can’t be denied, and his resume speaks for itself.
Siegall has always been interested in the power of technology and medicine, but he didn’t get interested in cancer research until he started studying zoology. He has a firm understanding of how deadly these diseases are, which is why he goes extremely hard to fight them. Rigorous research, scientific innovation and drug development are three of his strong principles of business. Seattle Genetics has many more drugs that are already in the pipeline. All in all, Dr. Clay Siegall is the real deal when it comes to fighter cancer, and his determination is a true testament of his success.